8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 1, 2007

DATASCOPE CORP.

(Exact name of registrant as specified in its charter)

Delaware	0-6516	13-2529596
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)
14 Philips Parkway
Montvale, New Jersey		07645-9998
(Address of principal executive offices)		(Zip Code)

(Registrant’s telephone number, including area code): (201) 391-8100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

          On October 1, 2007, Datascope Corp. issued a press release announcing that it has developed a new patient monitoring system called NetGuard. On October 3, 2007, Datascope Corp. issued a press release announcing the launch of a web-based software product called the Panorama Web Viewer. A copy of the NetGuard press release, dated October 1, 2007, and the Panorama Web Viewer press release, dated October 3, 2007, are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this report and are incorporated herein by reference.

          The information, including Exhibit 99.1 and Exhibit 99.2, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, except as shall otherwise be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

     (c) Exhibits:

Exhibit 99.1	Press release announcing the development of a new patient monitoring system called NetGuard, dated October 1, 2007, issued by Datascope Corp.
Exhibit 99.2	Press release announcing the launch of a web-based software product called the Panorama Web Viewer, dated October 3, 2007, issued by Datascope Corp.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

	DATASCOPE CORP. Registrant
	/s/ Henry M. Scaramelli
	Vice President,
	Chief Financial Officer
Dated: October 4, 2007

EXHIBIT INDEX

Exhibit 99.1	Press release announcing the development of a new patient monitoring system called NetGuard, dated October 1, 2007, issued by Datascope Corp.
Exhibit 99.2	Press release announcing the launch of a web-based software product called the Panorama Web Viewer, dated October 3, 2007, issued by Datascope Corp.

EX-99.1

Exhibit No. 99.1

PRESS RELEASE

For Information Contact:

Henry Scaramelli

Chief Financial Officer

Datascope Corp.

(201) 307-5435

www.datascope.com

FOR IMMEDIATE RELEASE:

Datascope Aims to Create New Growth Market
in Patient Monitoring

Montvale, NJ, October 1, 2007 . . . Datascope Corp. (NASDAQ: DSCP) today announced that it has developed a new patient monitoring system called NetGuard™ that uniquely and economically monitors the electrical activity of the heart (EKG) in order to protect the unmonitored hospital patient population in the event of a life-threatening heart rhythm.

A large majority of patients in hospitals throughout the world are currently unmonitored. In the United States, the Company believes that more than 100 million hospital patients annually are either not monitored at all or monitored only during a surgical or other procedure. Tens of thousands of unmonitored patients in U.S. hospitals die each year as a result of a dangerous heart rhythm. As the first monitoring system of its kind, NetGuard opens a potentially large new market in patient monitoring.

Continuous monitoring of patients allows immediate detection and early treatment of a dangerous heart rhythm, and has been shown to significantly increase survival. Yet, greater application of continuous monitoring is hampered by the cost of conventional patient monitoring equipment and by the cost of 24-hour staffing required by conventional central monitoring stations, which often exceeds the cost of the monitoring equipment. NetGuard was conceived to remove these barriers to continuous monitoring of unmonitored patients.

Commenting on the origin of NetGuard, Larry Saper, CEO and Founder of Datascope Corp. said, “We’ve been concerned for some time by reports of numerous and high profile incidents of patients dying of arrhythmia while unmonitored. With advances in technology, and proprietary innovations from our talented product development staff, we’ve been able to develop NetGuard which fulfills our long-awaited goal of creating a practical monitoring system to protect all patients who are currently unmonitored.”

The Company said that patent applications related to NetGuard technology have been filed, and are pending, in the United States and in major market countries worldwide.

The FDA approved Datascope’s 510(k) submission on September 26, 2007, giving the Company clearance to market the NetGuard system in the U.S. The Company plans a market launch in

November 2007. The NetGuard system also has a CE mark, and planning for market launch in Europe is currently underway.

The NetGuard system is simple, clinically effective and automatic. The heart of NetGuard is a very small wireless EKG monitor, weighing less than an ounce. The monitor communicates with a standard personal computer (PC) at a nurse’s station, which gives an alert and an EKG display when a dangerous rhythm is detected. A nurse typically would confirm the alert and call an emergency “code” in accordance with hospital protocol. One PC has the capacity to cover 50 patients. The system architecture of NetGuard provides for total coverage of a hospital.

The NetGuard system is also economical. The cost of the wireless system components, including the reusable portion of the EKG monitor, is a fraction of the cost of conventional monitors. The single-use component of the monitor, including batteries, electrode and adhesive pad are packaged together in a detachable unit that mates neatly with the reusable electronic unit. The batteries in the NetGuard monitor last three days — three times longer than conventional telemeters. Cost of the single-use component has not yet been established but will be affordable based on Datascope’s market research. The Company also believes that hospitals using the NetGuard System may reduce their potential exposure to liability from incidents to unmonitored patients that could have been prevented had monitoring been available. In addition, the Company believes that the availability of NetGuard may prove to be a competitive advantage to hospitals that use it.

About Datascope Corp.

Datascope Corp. is the global leader of intra-aortic balloon counterpulsation and a diversified medical device company that develops, manufactures and markets proprietary products for clinical health care markets in interventional cardiology and radiology, cardiovascular and vascular surgery, anesthesiology, emergency medicine and critical care. The Company has four product lines aggregated into two reporting segments, Cardiac Assist / Monitoring Products and Interventional / Vascular Products. The Company’s products are sold throughout the world through direct sales representatives and independent distributors. Founded in 1964, Datascope is headquartered in Montvale, New Jersey. For news releases, webcasts and other Company information please visit Datascope’s website, www.datascope.com.

Safe Harbor Statement

This press release contains forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. Many of these risks cannot be predicted or quantified and are at least partly outside our control, including the risk that the market may not find the NetGuard monitoring system to be sufficiently attractive to it in performance or utility, the risk that prospective customers may not be willing to incur the additional costs associated with the purchase and use of NetGuard, the risk that NetGuard may not be perceived as lowering liability risk or providing a competitive advantage to our customers, the risk that competition will develop for the segment of the market at which NetGuard is directed, the risk that NetGuard cannot be manufactured in commercial quantity at attractive margins, as well as other risks detailed in documents filed by Datascope with the Securities and Exchange Commission.

NetGuard Patient Monitor

NetGuard Alert Display

EX-99.2

Exhibit No. 99.2

PRESS RELEASE

For Information Contact:

Henry Scaramelli

Chief Financial Officer

Datascope Corp.

(201) 307-5435

www.datascope.com

FOR IMMEDIATE RELEASE:

Datascope Launches Web Based Remote Access Software
for Panorama™ Central Monitoring System

Panorama Web Viewer™ Product Further Expands the Company’s Position
in Worldwide Patient Monitoring Market

MONTVALE, NJ, October 3, 2007 . . . Datascope Corp. (NASDAQ: DSCP) today announced the U.S. launch of the Panorama Web Viewer, a web-based software product which enables remote access to patient data from virtually anywhere, using an Internet connected PC.

The Panorama Web Viewer allows clinicians with access to the hospital’s computer network the ability to view remotely any patient on the Datascope Panorama Central Monitoring System. The new software creates clinical desktops throughout a Wide Area Network (WAN) that provides streaming patient waveforms and vital signs. Patient trends can also be analyzed using a new intuitive graphic interface allowing the early recognition of changes in patient condition.

“The launch of the Panorama Web Viewer demonstrates our commitment to continually improve upon the capabilities of our Panorama Central Monitoring System. The addition of Web Viewer further expands our competitive position in larger, more sophisticated hospitals where remote access of patient data is required,” said David Gibson, President of Datascope’s Patient Monitoring Division.

During 2007, spending for hospital-based IT applications is projected to comprise nearly 40 percent of a hospital’s total capital budget. The Panorama Web Viewer enables hospitals to avoid additional expense by utilizing their existing IT infrastructures. The Panorama Web Viewer product expands the reach of the Panorama Central Monitoring System, enabling Datascope to aggressively compete within the estimated $1.3 billion central monitoring market.

About Datascope Corp.

Datascope Corp. is the global leader of intra-aortic balloon counterpulsation and a diversified medical device company that develops, manufactures and markets proprietary products for clinical health care markets in interventional cardiology and radiology, cardiovascular and vascular surgery, anesthesiology, emergency medicine and critical care. The Company’s

products are sold throughout the world through direct sales representatives and independent distributors. Founded in 1964, Datascope is headquartered in Montvale, New Jersey. For news releases, webcasts and other Company information please visit Datascope’s website, www.datascope.com.

Safe Harbor Statement

This press release contains forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. Many of these risks cannot be predicted or quantified and are at least partly outside our control, including the risk that the introduction of the Panorama Web Viewer will not expand the reach of the Panorama Central Monitoring System and will not enable us to aggressively compete within the $1.3 billion central monitoring market, as well as other risks detailed in documents filed by Datascope with the Securities and Exchange Commission.